Zepbound vs Ozempic Side Effects: A Head-to-Head Comparison

Why Side Effects Matter When Choosing Between Zepbound and Ozempic

Selecting a GLP-1-based medication often comes down to tolerability. Both Zepbound and Ozempic produce meaningful weight loss and glycemic improvement, but their side-effect profiles shape real-world adherence. A patient who cannot stay on a drug gains nothing from its efficacy.

Zepbound (tirzepatide) activates two incretin receptors: GIP and GLP-1. Ozempic (semaglutide) targets GLP-1 alone. That mechanistic difference changes how each drug affects gastric motility, appetite signaling, and, potentially, which side effects predominate [1]. No published randomized trial has directly compared Zepbound to Ozempic in a single protocol. The comparisons below synthesize data from their respective registration trials, SURMOUNT-1 for tirzepatide [1] and SUSTAIN-7 for semaglutide [2], with supplementary data from SURMOUNT-2, SURPASS-2, and SUSTAIN-1 through SUSTAIN-10 where relevant. Cross-trial comparisons carry inherent limitations: patient populations, titration schedules, baseline BMI, and diabetes status all differ. These caveats should inform, not prevent, a practical discussion of tolerability differences.

Gastrointestinal Side Effects: The Dominant Concern

GI events account for the majority of adverse effects reported with both drugs. Nausea, diarrhea, vomiting, and constipation appear in every GLP-1 receptor agonist trial, though their severity and duration vary.

In SURMOUNT-1 (N=2,539), participants received tirzepatide 5 mg, 10 mg, or 15 mg versus placebo over 72 weeks. Nausea occurred in 24.6% of the 5 mg group, 22.5% at 10 mg, and 23.6% at 15 mg. Vomiting rates were 8.3%, 10.7%, and 9.1%, respectively. Diarrhea affected 18.7%, 21.2%, and 16.2%. Constipation appeared in 5.8%, 7.5%, and 11.1% [1]. The pattern is notable: nausea did not meaningfully escalate with dose, but constipation did.

In SUSTAIN-7 (N=1,201), patients with type 2 diabetes received semaglutide 0.5 mg or 1.0 mg versus dulaglutide. Nausea affected 17.0% of the 0.5 mg group and 21.2% at 1.0 mg. Diarrhea occurred in 12.3% and 14.2%, respectively [2]. Vomiting rates were 7.0% at 0.5 mg and 8.0% at 1.0 mg. The SUSTAIN program consistently showed that GI events peaked during the first 8 to 12 weeks of treatment and then declined, a pattern also observed with tirzepatide in the SURMOUNT trials.

Dr. Ania Jastreboff, the lead investigator of SURMOUNT-1, has noted: "The gastrointestinal side effects with tirzepatide were most frequent during dose escalation and were predominantly mild to moderate in severity" (NEJM, 2022). This temporal clustering during titration is a shared feature of both drugs. Slow titration schedules (four weeks per dose step) appear to reduce peak nausea intensity for both medications.

Discontinuation Rates Due to Adverse Events

How often patients actually stop taking a medication is a harder endpoint than the simple occurrence of side effects. Mild nausea that resolves in two weeks differs sharply from persistent vomiting that forces discontinuation.

In SURMOUNT-1, adverse-event discontinuation rates were 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) for tirzepatide, compared to 2.6% for placebo [1]. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity noted that these rates were "within the range typically observed for injectable GLP-1 receptor agonists" (Endocrine Society, 2023). In SUSTAIN-7, discontinuation for adverse events was 5% for semaglutide 0.5 mg and 5% for 1.0 mg [2].

These numbers suggest roughly comparable tolerability at clinically effective doses. The 10 mg tirzepatide group showed the highest discontinuation rate at 7.1%, but the 15 mg group was actually lower at 6.2%, possibly reflecting that patients who tolerated 10 mg went on to tolerate 15 mg as well. For semaglutide, discontinuation held steady across doses, indicating consistent tolerability from 0.5 mg to 1.0 mg.

Nausea Timing and Management

Nausea is the single most common complaint with both Zepbound and Ozempic. Understanding when it peaks and how long it lasts helps clinicians set expectations.

With tirzepatide, nausea was reported as mild in roughly 52% of affected patients and moderate in about 39% during SURMOUNT-1 [1]. Severe nausea (requiring medical intervention or hospitalization) was rare, occurring in fewer than 2% of participants across all dose groups. The median duration of nausea episodes was approximately 6 to 9 days during each titration step, resolving for most patients before the next dose increase.

Semaglutide shows a similar pattern. In the STEP-1 trial (N=1,961), which studied semaglutide 2.4 mg for obesity (the dose used in Wegovy, not Ozempic), nausea affected 44.2% of participants [3]. At the lower Ozempic doses (0.5 to 1.0 mg), nausea rates in SUSTAIN trials ranged from 17% to 21%. The dose-response relationship is clearer for semaglutide: higher doses produce more nausea. For tirzepatide, the relationship is flatter, possibly because the GIP co-agonism modulates gastric emptying differently than GLP-1 agonism alone.

Practical nausea-management strategies are the same for both drugs: eat smaller meals, avoid high-fat foods during titration, stay hydrated, and consider ondansetron 4 to 8 mg if symptoms impair daily function. The American Gastroenterological Association has acknowledged that GLP-1 RA-related nausea is centrally mediated and not simply a gastric motility effect, which explains why antiemetics targeting the chemoreceptor trigger zone tend to work better than prokinetic agents.

Pancreatitis and Pancreatic Safety

Pancreatitis risk is a closely watched safety signal for all incretin-based therapies. Both tirzepatide and semaglutide carry labeling warnings about acute pancreatitis, though the absolute incidence in trials was very low.

In SURMOUNT-1, acute pancreatitis was reported in fewer than 0.2% of tirzepatide-treated participants across all doses [1]. The SURPASS program (which studied tirzepatide in type 2 diabetes) reported similarly low rates, with no statistically significant difference from comparator groups. Lipase and amylase elevations were observed more frequently (approximately 10 to 15% of patients showed values above the upper limit of normal), but most were asymptomatic and did not lead to clinical pancreatitis [4].

For semaglutide, the SUSTAIN program reported acute pancreatitis in 0.1 to 0.3% of participants. A pooled analysis published in The Lancet Diabetes & Endocrinology found no increased risk of pancreatitis with semaglutide compared to placebo or active comparators across the SUSTAIN and PIONEER trials [5]. The FDA's post-marketing surveillance database (FAERS) has not identified a clear causal signal linking either tirzepatide or semaglutide to pancreatitis above background population rates.

Patients with a history of pancreatitis should discuss risks individually with their prescriber. Both drugs should be stopped immediately if pancreatitis is suspected.

Thyroid C-Cell Tumor Warning

Both Zepbound and Ozempic carry a boxed warning about thyroid C-cell tumors based on rodent data. In preclinical studies, GLP-1 receptor agonists caused dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rats and mice [6].

The relevance to humans remains uncertain. Human thyroid C-cells express GLP-1 receptors at much lower density than rodent C-cells. To date, no clinical trial of tirzepatide or semaglutide has shown an increased incidence of MTC in humans. The FDA label for Ozempic states that "it is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" [6]. The same language appears on the Zepbound label.

Both drugs are contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Gallbladder Events

GLP-1 receptor agonists have been associated with an increased incidence of gallbladder-related events, including cholelithiasis and cholecystitis. Rapid weight loss itself increases gallstone formation, making it difficult to separate the pharmacological effect from the consequence of losing weight quickly.

In SURMOUNT-1, cholelithiasis was reported in 0.6% of the tirzepatide 15 mg group compared to 0% in placebo [1]. In SUSTAIN-6 (N=3,297, cardiovascular outcomes trial for semaglutide), cholelithiasis occurred in 1.5% of semaglutide patients versus 0.8% of placebo patients over 104 weeks [7]. The European Medicines Agency safety review has noted this signal for the entire GLP-1 RA class. Patients losing more than 1.5 kg per week may benefit from ursodiol prophylaxis, particularly if they have a prior history of gallstones.

Injection-Site Reactions and Hypoglycemia

Injection-site reactions were infrequent with both drugs. In SURMOUNT-1 to 3.2% of tirzepatide patients reported injection-site reactions, which were mostly erythema and pruritus at the injection site [1]. In SUSTAIN-7, semaglutide injection-site reactions occurred in approximately 1 to 2% of patients [2].

Hypoglycemia risk is low for both drugs when used without concomitant insulin or sulfonylureas. Neither tirzepatide nor semaglutide caused clinically significant hypoglycemia (blood glucose <54 mg/dL) at meaningful rates in their obesity trials. In diabetes trials, hypoglycemia was associated almost exclusively with background sulfonylurea or insulin use. As monotherapy or with metformin alone, both drugs showed hypoglycemia rates comparable to placebo.

Cardiovascular Safety and Non-GI Effects

Semaglutide has stronger cardiovascular outcome data than tirzepatide at this time. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease [8]. The tirzepatide cardiovascular outcomes trial, SURPASS-CVOT, is ongoing and results are expected by 2027.

Dr. A. Michael Lincoff, lead investigator of SELECT, stated: "Semaglutide reduced the risk of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in adults with pre-existing cardiovascular disease and overweight or obesity" (NEJM, 2023). This cardiovascular benefit may influence drug selection for patients with established heart disease, independent of side-effect considerations.

Heart rate increases of 2 to 4 beats per minute have been observed with both drugs in clinical trials. This effect is consistent across the GLP-1 RA class and is generally not clinically significant, though it should be monitored in patients with arrhythmias.

Putting the Comparison Together

Both Zepbound and Ozempic are well-tolerated GLP-1-based therapies with predictable, mostly gastrointestinal, side-effect profiles. The differences are subtle. Tirzepatide shows a flatter nausea-dose curve (nausea does not markedly increase from 5 mg to 15 mg), while semaglutide shows a steeper dose-response for nausea. Constipation is more prominent with higher-dose tirzepatide. Discontinuation rates are broadly similar at 5 to 7%.

Drug choice should account for tolerability alongside efficacy, insurance coverage, and patient-specific comorbidities. For patients with established cardiovascular disease, semaglutide has the SELECT trial behind it. For patients seeking maximum weight loss, tirzepatide's 20.9% body-weight reduction at 15 mg in SURMOUNT-1 exceeds what semaglutide achieves at Ozempic-range doses. Side effects alone rarely differentiate these two drugs enough to dictate the choice.

The recommended starting dose for Zepbound is 2.5 mg subcutaneously once weekly, titrated in 2.5 mg increments every four weeks to a maintenance dose of 5 mg, 10 mg, or 15 mg. For Ozempic, the starting dose is 0.25 mg once weekly for four weeks, then 0.5 mg, with an option to increase to 1 mg and then 2 mg based on glycemic response and tolerability.